3-Coumaranone derivatives as inhibitors of monoamine oxidase

被引:17
|
作者
Van Dyk, Adriaan S. [1 ,2 ]
Petzer, Jacobus P. [1 ,2 ]
Petzer, Anel [1 ]
Legoabe, Lesetja J. [1 ]
机构
[1] North West Univ, Ctr Excellence Pharmaceut Sci, ZA-2520 Potchefstroom, South Africa
[2] North West Univ, Pharmaceut Chem, Sch Pharm, ZA-2520 Potchefstroom, South Africa
来源
DRUG DESIGN DEVELOPMENT AND THERAPY | 2015年 / 9卷
基金
新加坡国家研究基金会; 英国医学研究理事会;
关键词
benzofuran-3(2H)-one; MAO; inhibition; reversible; competitive; Parkinson's disease; SELEGILINE TRANSDERMAL SYSTEM; SELECTIVE INHIBITORS; DISEASE;
D O I
10.2147/DDDT.S89961
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The present study examines the monoamine oxidase (MAO) inhibitory properties of a series of 20 3-coumaranone [benzofuran-3(2H)-one] derivatives. The 3-coumaranone derivatives are structurally related to series of alpha-tetralone and 1-indanone derivatives, which have recently been shown to potently inhibit MAO, with selectivity for MAO-B (in preference to the MAO-A isoform). 3-Coumaranones are similarly found to selectively inhibit human MAO-B with half-maximal inhibitory concentration (IC50) values of 0.004-1.05 mu M. Nine compounds exhibited IC50<0.05 mu M for the inhibition of MAO-B. For the inhibition of human MAO-A, IC50 values ranged from 0.586 to >100 mu M, with only one compound possessing an IC50<1 mu M. For selected 3-coumaranone derivatives, it is established that MAO-A and MAO-B inhibition are reversible since dialysis of enzyme-inhibitor mixtures almost completely restores enzyme activity. On the basis of the selectivity profiles and potent action, it may be concluded that the 3-coumaranone derivatives are suitable leads for the development of selective MAO-B inhibitors as potential treatment for disorders such as Parkinson's disease and Alzheimer's disease.
引用
收藏
页码:5479 / 5489
页数:11
相关论文
共 50 条
  • [21] MONOAMINE OXIDASE INHIBITORS
    JOHNSON, AG
    CUTHBERT, MF
    BRITISH MEDICAL JOURNAL, 1968, 2 (5602): : 433 - &
  • [22] MONOAMINE OXIDASE INHIBITORS
    MASTERS, AB
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1971, 105 (12) : 1281 - &
  • [23] Computational Exploration of Xanthones Derivatives as Potent Inhibitors of Monoamine Oxidase
    El Masaoudy, Yassine
    Alaqarbeh, Marwa
    Maghat, Hamid
    Lakhlifi, Tahar
    Bouachrine, Mohammed
    JORDAN JOURNAL OF CHEMISTRY, 2024, 19 (02) : 107 - 123
  • [24] MONOAMINE OXIDASE INHIBITORS
    MUNRO, JS
    ANAESTHESIA, 1965, 20 (01) : 97 - &
  • [25] MONOAMINE OXIDASE INHIBITORS
    不详
    BRITISH MEDICAL JOURNAL, 1959, 2 (DEC5): : 1238 - 1238
  • [26] STRUCTURE AND ACTIVITY RELATIONSHIP OF MONOAMINE OXIDASE INHIBITORS, PHENYLACETYLHYDRAZIDE DERIVATIVES
    NAKAMURA, K
    MASUDA, Y
    TATSUMI, H
    FUJIMOTO, K
    JAPANESE JOURNAL OF PHARMACOLOGY, 1963, 13 (02): : 186 - &
  • [27] Current Progress in Quinazoline Derivatives as Acetylcholinesterase and Monoamine Oxidase Inhibitors
    Rehuman, Nisha Abdul
    Al-Sehemi, Abdullah G.
    Parambi, Della Grace Thomas
    Rangarajan, T. M.
    Nicolotti, Orazio
    Kim, Hoon
    Mathew, Bijo
    CHEMISTRYSELECT, 2021, 6 (28): : 7162 - 7182
  • [28] MONOAMINE OXIDASE INHIBITORS
    LEWIS, JJ
    PRACTITIONER, 1964, 192 (114) : 172 - &
  • [29] The enantioselective hydrogenation of 3-coumaranone over chiral centres generated on a Pt/silica catalyst
    Allan, E
    Jackson, SD
    Korn, S
    Webb, G
    Young, N
    CATALYSIS OF ORGANIC REACTIONS, 1996, 68 : 191 - 198
  • [30] Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors
    Vilches-Herrera, Marcelo
    Miranda-Sepulveda, Juan
    Rebolledo-Fuentes, Marco
    Fierro, Angelica
    Luehr, Susan
    Iturriaga-Vasquez, Patricio
    Cassels, Bruce K.
    Reyes-Parada, Miguel
    BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (06) : 2452 - 2460